Perioperative Anticoagulation Management

Introduction to Anticoagulation Therapy

• The American College of Chest Physicians recommends that unfractionated heparin (UFH) be discontinued 4-6 hours before surgery to completely eliminate its anticoagulant effect, with a half-life of approximately 90 minutes, but this can vary between 30-120 minutes depending on the level of anticoagulation at the time of discontinuation 1, 2
• The American Heart Association suggests that an interval of 4-6 hours allows the anticoagulant effect to be completely eliminated before surgery, and UFH can be restarted without a bolus more than 4 hours after removal of the peripheral venous catheter 2, 3

Low Molecular Weight Heparin (LMWH) Therapy

• The American College of Chest Physicians recommends that the last preoperative dose of enoxaparina, a type of LMWH, be administered 24 hours before surgery, not 12 hours before, to minimize the risk of perioperative bleeding, as LMWHs have a half-life of 3-5 hours 1, 4
• Studies demonstrate that more than 90% of patients who receive their last dose of LMWH approximately 12 hours before surgery have detectable anticoagulant effect at the time of surgery, and 34% have therapeutic levels (anti-factor Xa ≥0.50 UI/mL), highlighting the importance of proper timing 1
• The recommended protocol for LMWH involves administering the last preoperative dose 24 hours before the procedure, at half of the total daily dose, to reduce the risk of major bleeding compared to administering the full dose 12 hours before 1, 5

Special Considerations for LMWH

• For procedures with neuroaxial anesthesia, prophylactic doses of LMWH once daily should not be administered within 10-12 hours before the procedure, and the first dose of LMWH can be administered no earlier than 2 hours after removal of the epidural catheter, according to guidelines from the American Society of Regional Anesthesia and Pain Medicine 6
• Patients with a high risk of thromboembolism should have heparin initiated when the INR falls below 2.0 if they are transitioning from warfarin, as recommended by the American Heart Association 2, 3

Postoperative Anticoagulation Management

• The American College of Chest Physicians suggests restarting UFH ≥24 hours after elective surgery, avoiding bolus doses and starting with a lower-intensity infusion, to minimize the risk of bleeding 1
• For LMWH, the American College of Chest Physicians recommends restarting at a therapeutic dose within 24 hours for low-risk procedures, but waiting 48-72 hours or using intermediate/prophylactic doses for high-risk procedures, such as spinal laminectomy, to minimize the risk of major bleeding 5

Restarting Heparin After Medical Procedures

Timing of Heparin Restart

• The American College of Cardiology recommends restarting therapeutic-dose heparin within 24 hours after low-bleeding risk procedures, once hemostasis is confirmed, while delaying restart to 48-72 hours postoperatively for high-bleeding risk procedures 7, 8
• For low-bleeding risk procedures, such as minor surgeries or dental procedures, full therapeutic-dose heparin can be restarted within 24 hours after the procedure 7, 9
• Unfractionated heparin can be restarted without a bolus more than 4 hours after removal of the peripheral venous catheter or sheath, in patients who have undergone low-bleeding risk procedures 9
• After high-bleeding risk procedures, such as major surgery, full-dose therapeutic heparin or LMWH should be delayed for 48-72 hours before resuming 7
• Intermediate-dose or prophylactic-dose LMWH can be used during the initial 48-72 hour period after high-bleeding risk procedures to balance thrombotic and bleeding risks 7

Patient Stratification and Heparin Regimen

• For patients at high thrombotic risk, such as those with mechanical mitral valve or recent stroke, earlier restart of heparin can be considered even after high-bleeding risk procedures 8, 9
• The American Heart Association suggests that patients with high thrombotic risk, including those with severe thrombophilia or antiphospholipid syndrome, should have heparin restarted at 12-24 hours if hemostasis is excellent 7, 8
• Low molecular weight heparin (LMWH) can be restarted at full therapeutic dose within 24 hours after low-risk procedures, while intermediate or prophylactic doses can be used for 48-72 hours after high-risk procedures before advancing to therapeutic dosing 7

Special Considerations

• Therapeutic bridging with heparin should be continued until the international normalized ratio (INR) reaches a therapeutic range, typically greater than 1.9, in patients on chronic anticoagulation requiring bridging 7
• For patients requiring only venous thromboembolism (VTE) prophylaxis, empiric low-dose heparin can be started within 24 hours after surgery and continued for up to 5 days while oral anticoagulation is resumed, as recommended by the American College of Chest Physicians 8
• Restarting therapeutic-dose LMWH within 12-24 hours of high-bleeding risk surgery can increase the risk of major bleeding, with rates reaching up to 20% when bridging therapy is given too close to surgery 7

Stopping Unfractionated Heparin Before Procedures

Procedure-Specific Considerations

• Neuraxial procedures, such as spinal anesthesia, epidurals, and lumbar punctures, are contraindicated under active anticoagulation, as recommended by the Anaesthesia guideline society 10
• For patients with acute Heparin-Induced Thrombocytopenia (HIT), the Anaesthesia guideline society recommends stopping Argatroban infusion 4 hours before surgery 10
• For patients with acute Heparin-Induced Thrombocytopenia (HIT), the Anaesthesia guideline society recommends stopping Bivalirudin infusion 2 hours before surgery 10
• Argatroban and Bivalirudin have shorter half-lives, approximately 50 minutes and 20-30 minutes, respectively, as noted by the Anaesthesia guideline society 10

Perioperative Timing and Management of Heparin Anticoagulation

Pre‑operative Discontinuation of Unfractionated Heparin (UFH)

• Intravenous UFH should be stopped 4–6 hours before the surgical incision to allow >90 % drug clearance (half‑life ≈ 90 min, range 30–120 min)【11】.
• Subcutaneous UFH has a more prolonged anticoagulant effect than the intravenous formulation and may require a longer discontinuation interval【12】.
• In patients with severe renal insufficiency or on dialysis, UFH is the preferred bridging agent because LMWH should be avoided【11】.

Pre‑operative Discontinuation of Therapeutic‑dose Low‑Molecular‑Weight Heparin (LMWH)

• The last therapeutic LMWH dose should be given ≈ 24 hours before surgery (not 12 hours) to ensure adequate clearance【11】.
• When LMWH is administered twice daily, the final dose should be omitted entirely rather than reduced【11】.
• When LMWH is administered once daily, give half of the usual daily dose the morning before surgery (approximately 36 hours pre‑op) to minimize residual activity【11】.
• Giving the last LMWH dose only 12 hours before surgery leaves therapeutic anti‑factor Xa levels in >30 % of patients at incision time【11】.

Renal‑Impairment Considerations

• Therapeutic‑dose LMWH should be avoided in patients with creatinine clearance < 30 mL/min because of drug accumulation; switch to IV UFH for bridging【11】.
• UFH remains the preferred bridging agent in severe renal dysfunction, as it is primarily cleared by hepatic and reticulo‑endothelial pathways【11】.

Post‑operative Resumption of Heparin

• Low‑bleeding‑risk surgeries: resume therapeutic‑dose heparin within 24 hours after achieving hemostasis【11】.
• High‑bleeding‑risk surgeries (e.g., major, neurosurgical, spinal procedures): delay resumption 48–72 hours post‑operatively【11】.
• Restart IV UFH without a bolus, using the pre‑operative infusion rate, ≥ 4 hours after removal of epidural catheters or surgical drains【11】; consider a lower‑intensity infusion and a reduced aPTT target initially.
• Resume therapeutic‑dose LMWH ≥ 12 hours after the last prophylactic LMWH dose to avoid overlapping anticoagulant effects【11】.
• Initiating therapeutic‑dose LMWH within 12–24 hours of major surgery is associated with a ≈ 20 % incidence of major bleeding【11】.

Identification of High‑Risk Thrombotic Patients (Bridging Indications)

• Recent venous thrombo‑embolism (≤ 3 months)
• Mechanical prosthetic heart valve, especially in the mitral position
• Atrial fibrillation with CHADS₂ score ≥ 5
• Recent stroke or transient ischaemic attack (≤ 3 months)

Common Pitfalls to Avoid (Evidence‑based)

• Do not administer the final LMWH dose 12 hours before surgery; this timing leaves therapeutic anticoagulation at incision【11】.
• Do not restart therapeutic heparin earlier than recommended post‑operatively, as major bleeding rates can reach 20 % when bridging is begun within 12–24 hours after major surgery【11】.
• Do not use a bolus dose when restarting IV UFH after surgery, because it markedly increases bleeding risk【11】.
• Do not use therapeutic‑dose LMWH for bridging in patients with severe renal impairment (CrCl < 30 mL/min); instead, employ monitored IV UFH【11】.
• Do not provide heparin bridging for atrial‑fibrillation patients undergoing colonoscopy with anticipated polypectomy, as the bleeding risk outweighs the thrombotic benefit【12】.